Αποτελέσματα Αναζήτησης
15 Οκτ 2010 · In the placebo-controlled phase III SATURN study, maintenance erlotinib after first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) and overall survival (OS) in the overall study population of patients with advanced non-small-cell lung cancer (NSCLC).
The Sequential Tarceva in Unresectable NSCLC (SATURN) study investigated the use of maintenance erlotinib following the completion of first-line chemotherapy.
24 Μαΐ 2011 · In the phase III SequentiAl Tarceva in UnResectable NSCLC (SATURN; BO18192) study, maintenance therapy with erlotinib significantly increased progression-free and overall survival (PFS and OS) versus placebo in both the overall intention-to-treat (ITT) population and in patients with EGFR immunohistochemistry (IHC)-positive tumours [13]. These
2 Αυγ 2009 · August 1, 2009 (San Francisco, California) — New results from the phase 3 SATURN trial show that erlotinib (Tarceva) maintenance therapy significantly improves overall survival in...
20 Δεκ 2010 · Recently, Cappuzzo et al Citation 50 presented data from the Sequential Tarceva in Unresectable NSCLC (SATURN) trial a double-blind, randomized, phase III study of maintenance erlotinib vs placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. The final results of the study found that the ...
20 Μαΐ 2009 · SATURN (Sequential Tarceva in Unresectable NSCLC) 73 is a randomized, placebo-controlled phase III trial in which erlotinib was evaluated as first-line maintenance therapy in advanced NSCLC...
23 Απρ 2018 · The controlled phase III trial SATURN demonstrated that maintenance therapy with erlotinib after the first-line platinum-based chemotherapy prolonged progression-free survival (PFS) and overall survival (OS) of non-small cell lung cancer (NSCLC) patients with advanced, non-progressive disease.
